1. Home
  2. MRKR vs LRE Comparison

MRKR vs LRE Comparison

Compare MRKR & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.40

Market Cap

18.7M

Sector

Health Care

ML Signal

HOLD

Logo Lead Real Estate Co. Ltd

LRE

Lead Real Estate Co. Ltd

HOLD

Current Price

$1.30

Market Cap

17.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRKR
LRE
Founded
1999
2001
Country
United States
Japan
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.7M
17.7M
IPO Year
2010
2022

Fundamental Metrics

Financial Performance
Metric
MRKR
LRE
Price
$1.40
$1.30
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
54.6K
8.0K
Earning Date
05-14-2026
07-30-2015
Dividend Yield
N/A
N/A
EPS Growth
33.61
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$936.27
N/A
P/E Ratio
N/A
$3.16
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$1.00
52 Week High
$2.46
$2.86

Technical Indicators

Market Signals
Indicator
MRKR
LRE
Relative Strength Index (RSI) 62.15 51.14
Support Level $1.35 $1.20
Resistance Level $1.54 $1.37
Average True Range (ATR) 0.09 0.06
MACD 0.03 0.00
Stochastic Oscillator 88.76 54.17

Price Performance

Historical Comparison
MRKR
LRE

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

Share on Social Networks: